P

Inventor

CLAREMON DAVID A

US147 patents
⚠️ This page may combine multiple inventors who share the name “CLAREMON DAVID A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MERCK & CO INC

31 patents
US5859041AJan 12, 1999

Substituted imidazoles having cytokine inhibitory activity

MERCK & CO INC135 citations98
US5717100AFeb 10, 1998

Substituted imidazoles having anti-cancer and cytokine inhibitory activity

MERCK & CO INC116 citations98
US5633251AMay 27, 1997

N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines

MERCK & CO INC90 citations96
US5633247AMay 27, 1997

Nitrogen-containing spirocycles

MERCK & CO INC73 citations96
US5595990AJan 21, 1997

Antiarrhythmic benzodiazepines

MERCK & CO INC61 citations96
US5389631AFeb 14, 1995

Fibrinogen receptor antagonists

MERCK & CO INC58 citations96
US5215989AJun 1, 1993

Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents

MERCK & CO INC108 citations96
US5206240AApr 27, 1993

Nitrogen-containing spirocycles

MERCK & CO INC77 citations96
US5032598AJul 16, 1991

Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents

MERCK & CO INC58 citations96
US5030644AJul 9, 1991

Imidazole compounds and their use as transglutaminase inhibitors

MERCK & CO INC72 citations96
US6083949AJul 4, 2000

Substituted imidazoles having anti-cancer and cytokine inhibitory activity

MERCK & CO INC28 citations93
US5658901AAug 19, 1997

2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines

MERCK & CO INC38 citations93
US5098707AMar 24, 1992

Imidazole compounds and their use as transglutaminase inhibitors

MERCK & CO INC29 citations93
US6870055B2Mar 22, 2005

Isoquinolinone potassium channels inhibitors

MERCK & CO INC28 citations92
US6376530B1Apr 23, 2002

Cyclic amidines useful as NMDA NR2B antagonists

MERCK & CO INC22 citations92
US6316474B1Nov 13, 2001

2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists

MERCK & CO INC43 citations92
US6303637B1Oct 16, 2001

Heterocyclic potassium channel inhibitors

MERCK & CO INC39 citations92
US6207687B1Mar 27, 2001

Substituted imidazoles having cytokine inhibitory activity

MERCK & CO INC21 citations92
US6194458B1Feb 27, 2001

Benzamide potassium channel inhibitors

MERCK & CO INC43 citations92
US5726171AMar 10, 1998

N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides

MERCK & CO INC20 citations92
US5426185AJun 20, 1995

Antiarrhythmic benzodiazepines

MERCK & CO INC21 citations92
US5112824AMay 12, 1992

Benzofuran compounds as class III antiarrhythmic agents

MERCK & CO INC25 citations92
US6632836B1Oct 14, 2003

Carbocyclic potassium channel inhibitors

MERCK & CO INC45 citations90
US7592360B2Sep 22, 2009

3-fluoro-piperidines as NMDA/NR2B antagonists

MERCK & CO INC18 citations84
US6403596B1Jun 11, 2002

Substituted pyridones having cytokine inhibitory activity

MERCK & CO INC14 citations84
US7259157B2Aug 21, 2007

N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

MERCK & CO INC12 citations83
US7053089B2May 30, 2006

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

MERCK & CO INC13 citations82
US6476041B1Nov 5, 2002

1,4 substituted piperidinyl NMDA/NR2B antagonists

MERCK & CO INC16 citations79
US6492516B1Dec 10, 2002

Compounds having cytokine inhibitory activity

MERCK & CO INC9 citations74
US5696111ADec 9, 1997

3-acylaminobenzazepines

MERCK & CO INC13 citations74
US5691332ANov 25, 1997

N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides

MERCK & CO INC15 citations74

VITAE PHARMACEUTICALS INC

9 patents

VITAE PHARMACEUTICALS LLC

5 patents

CLAREMON DAVID A

4 patents

CACATIAN SALVACION

1 patent

Showing the top 50 of 147 patents by PatentIndex Score.